Medonyx Drugs And Nutraceuticals Profile
Key Indicators
- Authorised Capital ₹ 0.10 M
as on 25-05-2024
- Paid Up Capital ₹ 0.10 M
as on 25-05-2024
- Company Age 5 Year, 10 Months
- Last Filing with ROC 31 Mar 2023
- Revenue -17.54%
(FY 2022)
- Profit 3517.96%
(FY 2022)
- Ebitda -20.22%
(FY 2022)
- Net Worth 200.61%
(FY 2022)
- Total Assets -44.19%
(FY 2022)
About Medonyx Drugs And Nutraceuticals
The Company is engaged in the Healthcare Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 0.10 M and a paid-up capital of Rs 0.10 M, as per Ministry of Corporate Affairs (MCA) records.
Sanju Bala and Rekha Rani serve as directors at the Company.
- CIN/LLPIN
U85100DL2019PTC346458
- Company No.
346458
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
22 Feb 2019
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Delhi
Industry
Company Details
- Location
South West Delhi, Delhi, India
- Telephone
- Email Address
- Website
-
- Social Media-
What products or services does Medonyx Drugs And Nutraceuticals Private Limited offer?
Medonyx Drugs And Nutraceuticals Private Limited offers a wide range of products and services, including Anti Infective Drugs & Medicines, Antibacterial Drugs.
Who are the key members and board of directors at Medonyx Drugs And Nutraceuticals?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Sanju Bala  | Director | 22-Feb-2019 | Current |
| Rekha Rani | Director | 09-Oct-2019 | Current |
Financial Performance of Medonyx Drugs And Nutraceuticals.
Medonyx Drugs And Nutraceuticals Private Limited, for the financial year ended 2022, experienced significant reduction in revenue, with a 17.54% decrease. The company also saw a substantial improvement in profitability, with a 3517.96% increase in profit. The company's net worth Soared by an impressive increase of 200.61%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Medonyx Drugs And Nutraceuticals?
Unlock access to Medonyx Drugs And Nutraceuticals's control and ownership data, Corporate Shareholding Patterns, Funding (security allotment) details, Foreign Institutional Investor information, Directors and Key Management Personnel (KMP) Remuneration, Group Structure, Overseas Direct Investment and other pertinent data.
Related Corporates (Common Directorship)
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Medonyx Drugs And Nutraceuticals?
Unlock and access historical data on people associated with Medonyx Drugs And Nutraceuticals, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Medonyx Drugs And Nutraceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Medonyx Drugs And Nutraceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
